Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial respiratory complex I (NADH:ubiquinone oxidoreductase) is the entry point for electrons into the respiratory chain, coupling NADH oxidation to proton translocation. The FMN-associated secondary quinone site, also known as Site IF, is located in the peripheral arm of the complex near the flavin mononucleotide cofactor. While the primary Q-site reduces physiological ubiquinone, the FMN-associated site is capable of reducing artificial quinones and serves as a critical hub for the generation of reactive oxygen species (ROS). This site is the primary target for biguanides like metformin, which inhibit the enzyme's activity to modulate cellular energy metabolism and reduce oxidative stress. Targeting this site is central to the management of type 2 diabetes and is being investigated for its potential to selectively disrupt cancer cell metabolism and protect against neurodegeneration.
Inhibition of NADH oxidation, suppression of mitochondrial ROS production, and indirect activation of AMPK through alteration of the ATP/AMP ratio.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial respiratory complex I – FMN-associated secondary quinone site (Complex I FMN site).